Greenrise Global’s Supports Germany’s Approach to Cannabis Legalization for Adult Use

2.4 min readPublished On: November 25th, 2021By

BERLIN and ERFURT, Germany – Greenrise Global Brands Inc. (formerly AMP Alternative Medical Products Inc.) (Frankfurt: C4T) (ISIN: CA39540L1085) (CSE: XCX) would like to comment on the German coalition government’s (SPD, Alliance 90/The Greens and FDP) announcement to legalize the sale of cannabis for consumption purposes to adults in licensed stores with the objective to control quality and ensure the protection of minors.

With a population of over 83 million and the world’s fourth-largest economy, Germany will be the third country to legalize adult-use and only the second G-7 nation to do so and the first on the European continent.

The Institute for Competition Economics (DICE) at the Heinrich Heine University in Duesseldorf, and commissioned by the German hemp association, found that legalizing cannabis could lead to additional tax revenues of more than €4.7 billion per year and create roughly 27,000 new jobs.

Greenrise Global Brands Inc. operates in the CBD wellbeing consumer and medical cannabis markets in Germany.

Dr. Stefan Feuerstein, President and Director of Greenrise Global, commented, “Our strategy is to be a leader in the German cannabis market and to build one of the most experienced management teams specifically to capitalize on this opportunity. Our executive team experience includes successfully bidding and building Germany’s first medical cultivation facility and building one of the leading medical cannabis companies.”

Mr. Hendrik Knopp, Director of Greenrise Global, commented, “Vision, leadership and ability to execute will define who leads in Germany. Greenrise Global was created with the vision to be a German leader. Our ability to import cannabis from within and outside Europe into Germany and our nationwide pharmaceutical supply and sales network in addition to our knowledge and customer base in wellbeing and medical uniquely position us to lead.”

Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accept responsibility for the adequacy or accuracy of this release.

This news release contains forward-looking statements that are based on the Company’s expectations, estimates and projections regarding its business and the economic environment in which it operates, including with respect to its business plans and milestones and the timing thereof. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements do not guarantee future performance and involve risks and uncertainties that are difficult to control or predict. Therefore, actual outcomes and results may differ materially from those expressed in these forward-looking statements and readers should not place undue reliance on such statements. These forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances unless otherwise required to do so by law.

(This information is primarily sourced from Greenrise Global Brands Inc.  Highly Capitalized has neither approved nor disapproved the contents of this news release. Read our Disclaimer here).

About the Author: HCN News Team

The News Team at Highly Capitalized are some of the most experienced writers in cannabis and psychedelics business & finance. We cover capital markets, finance, branding, marketing and everything important in between. Most of all, we follow the money.

Share This Story, Choose Your Platform!